1. Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis.
- Author
-
Leon Di Stefano, Elizabeth L Ogburn, Malathi Ram, Daniel O Scharfstein, Tianjing Li, Preeti Khanal, Sheriza N Baksh, Nichol McBee, Joshua Gruber, Marianne R Gildea, Megan R Clark, Neil A Goldenberg, Yussef Bennani, Samuel M Brown, Whitney R Buckel, Meredith E Clement, Mark J Mulligan, Jane A O'Halloran, Adriana M Rauseo, Wesley H Self, Matthew W Semler, Todd Seto, Jason E Stout, Robert J Ulrich, Jennifer Victory, Barbara E Bierer, Daniel F Hanley, Daniel Freilich, and Pandemic Response COVID-19 Research Collaboration Platform for HCQ/CQ Pooled Analyses
- Subjects
Medicine ,Science - Abstract
BackgroundResults from observational studies and randomized clinical trials (RCTs) have led to the consensus that hydroxychloroquine (HCQ) and chloroquine (CQ) are not effective for COVID-19 prevention or treatment. Pooling individual participant data, including unanalyzed data from trials terminated early, enables more detailed investigation of the efficacy and safety of HCQ/CQ among subgroups of hospitalized patients.MethodsWe searched ClinicalTrials.gov in May and June 2020 for US-based RCTs evaluating HCQ/CQ in hospitalized COVID-19 patients in which the outcomes defined in this study were recorded or could be extrapolated. The primary outcome was a 7-point ordinal scale measured between day 28 and 35 post enrollment; comparisons used proportional odds ratios. Harmonized de-identified data were collected via a common template spreadsheet sent to each principal investigator. The data were analyzed by fitting a prespecified Bayesian ordinal regression model and standardizing the resulting predictions.ResultsEight of 19 trials met eligibility criteria and agreed to participate. Patient-level data were available from 770 participants (412 HCQ/CQ vs 358 control). Baseline characteristics were similar between groups. We did not find evidence of a difference in COVID-19 ordinal scores between days 28 and 35 post-enrollment in the pooled patient population (odds ratio, 0.97; 95% credible interval, 0.76-1.24; higher favors HCQ/CQ), and found no convincing evidence of meaningful treatment effect heterogeneity among prespecified subgroups. Adverse event and serious adverse event rates were numerically higher with HCQ/CQ vs control (0.39 vs 0.29 and 0.13 vs 0.09 per patient, respectively).ConclusionsThe findings of this individual participant data meta-analysis reinforce those of individual RCTs that HCQ/CQ is not efficacious for treatment of COVID-19 in hospitalized patients.
- Published
- 2022
- Full Text
- View/download PDF